BIO-key International (NASDAQ: BKYI) Q2 Earnings Preview: Revenue Growth and Profitability in Focus

• BIO-key International (NASDAQ: BKYI) will host its second-quarter 2026 investor call on Friday, August 14, 2026, at 10:00 a.m. ET.
• Management previously projected approximately $2.8 million in Q2 revenue, representing growth of about 65% from $1.7 million in the prior-year quarter.
• Although BIO-key expected to achieve profitability during the first half of 2026, investors should consider its history of losses, negative operating cash flow, financing requirements, and going-concern risk.

BIO-key International (NASDAQ: BKYI), a provider of identity security and biometric authentication solutions, will host its Q2 2026 investor call on August 14, 2026, at 10:00 a.m. ET. Chairman and CEO Mike DePasquale and CFO Cecilia Welch will lead the call and question-and-answer session.

BIO-key previously projected that its Q2 revenue would increase approximately 65% to $2.8 million, compared with $1.7 million in Q2 2025. The company also expected first-half 2026 revenue to rise approximately 50% to $5 million and anticipated achieving first-half profitability, compared with a $1.9 million net loss in the prior-year period. These projections were provided by management and remain forward-looking estimates rather than reported results.

During Q1 2026, BIO-key generated revenue of approximately $2.15 million, up about 34% year over year. Its net loss narrowed to approximately $165,000, or $0.15 per share, from a net loss of approximately $737,000, or $1.57 per share, in Q1 2025. Per-share amounts reflect the company’s one-for-ten reverse stock split completed on April 30, 2026.

BIO-key recently announced that it and Portuguese technology partner Visualforma secured a contract with a Portuguese national security agency. The company also formed a strategic partnership with Maktabi Tech to pursue opportunities in Saudi Arabia’s education sector. 

Despite the growth outlook, BIO-key continues to face meaningful financial risks. Its latest quarterly filing reported approximately $2.25 million in cash, negative operating cash flow, and working capital of about $1.3 million. Management also stated that recurring losses, negative operating cash flow, and dependence on additional financing raised substantial doubt about the company’s ability to continue as a going concern.

The company’s current ratio of approximately 1.41 indicates that current assets exceeded current liabilities at the end of the latest reported quarter. However, this ratio alone does not establish strong financial stability. Investors should also consider BIO-key’s cash requirements, operating losses, customer concentration, potential dilution from equity financing, and reliance on converting its sales pipeline into revenue.

Valuation ratio such as a negative enterprise-value-to-operating-cash-flow ratio provides limited analytical value when a company reports negative operating cash flow. For BIO-key, Q2 revenue growth, gross margin, operating cash flow, liquidity, and management’s progress toward sustainable profitability are likely to be more informative measures of its financial performance.